 HIV-1
"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 12 | 5 | 17 | | 1996 | 9 | 4 | 13 | | 1997 | 5 | 1 | 6 | | 1998 | 13 | 2 | 15 | | 1999 | 10 | 0 | 10 | | 2000 | 13 | 4 | 17 | | 2001 | 8 | 3 | 11 | | 2002 | 11 | 4 | 15 | | 2003 | 8 | 3 | 11 | | 2004 | 12 | 7 | 19 | | 2005 | 11 | 7 | 18 | | 2006 | 17 | 1 | 18 | | 2007 | 11 | 3 | 14 | | 2008 | 13 | 8 | 21 | | 2009 | 10 | 3 | 13 | | 2010 | 20 | 4 | 24 | | 2011 | 23 | 6 | 29 | | 2012 | 19 | 8 | 27 | | 2013 | 17 | 5 | 22 | | 2014 | 28 | 12 | 40 | | 2015 | 16 | 7 | 23 | | 2016 | 22 | 9 | 31 | | 2017 | 14 | 13 | 27 | | 2018 | 16 | 7 | 23 | | 2019 | 12 | 5 | 17 | | 2020 | 12 | 8 | 20 | | 2021 | 11 | 6 | 17 | | 2022 | 19 | 1 | 20 | | 2023 | 13 | 0 | 13 | | 2024 | 11 | 4 | 15 | | 2025 | 11 | 4 | 15 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
-
Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.
-
Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci Transl Med. 2025 Jul 30; 17(809):eady6831.
-
Panja S, Zaman LA, Zhang C, Patel M, Gorantla S, Dash PK, Gendelman HE. Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV-1 Proviral DNA Excision. Adv Healthc Mater. 2025 Sep; 14(25):e2501190.
-
Mann BT, Sanz M, Clohosey ML, Langlands K, Chitrakar A, Moreno-Soriano C, Vitalle J, Iannone MA, Ruiz-Mateos E, Deleage C, Siegel M, Soriano-Sarabia N. Dual role of circulating and mucosal Vd1 T cells in the control of and contribution to persistent HIV-1 infection. Nat Commun. 2025 Jul 01; 16(1):5817.
-
Filsinger Interrante MV, Tang S, Kim S, Shanker VR, Hie BL, Bruun TUJ, Wu W, Pak JE, Fernandez D, Kim PS. Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat. ACS Chem Biol. 2025 Jul 18; 20(7):1470-1480.
-
Rabie H, Yin DE, Ward S, Rani Y, Ziemba L, Brooks KM, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Flynn PM. Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results. Pediatr Infect Dis J. 2025 May 29; 44(8):777-784.
-
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun. 2025 May 18; 16(1):4617.
-
Briganti L, Annamalai AS, Bester SM, Wei G, Andino-Moncada JR, Singh SP, Kleinpeter AB, Tripathi M, Nguyen B, Radhakrishnan R, Singh PK, Greenwood J, Schope LI, Haney R, Huang S-W, Freed EO, Engelman AN, Francis AC, Kvaratskhelia M. Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir. mBio. 2025 May 14; 16(5):e0361324.
-
Feist WN, Luna SE, Ben-Efraim K, Filsinger Interrante MV, Amorin A, Johnston NM, Bruun TUJ, Utz A, Ghanim HY, Lesch BJ, McLaughlin TM, Dudek AM, Porteus MH. Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies. Nat Commun. 2025 Apr 01; 16(1):3103.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|